---
title: Cancer Immunotherapy
type: content
phase: 1
status: complete
priority: high
tags: [immunotherapy, checkpoint-inhibitors, PD-1, PD-L1, CTLA-4, CAR-T, pembrolizumab, nivolumab, ipilimumab, immune-related-adverse-events]
created: 2025-11-08
last_modified: 2025-11-08
---

# Cancer Immunotherapy

## Introduction

Cancer immunotherapy harnesses the patient's immune system to recognize and destroy cancer cells. Immune checkpoint inhibitors, CAR-T cell therapy, and other immunotherapeutic approaches have revolutionized cancer treatment, achieving durable responses in previously untreatable cancers.

## Immune Checkpoint Biology

### Normal Immune Regulation

**Immune Checkpoints**: Regulate immune responses (prevent autoimmunity)

**Key Checkpoints**:

1. **CTLA-4** (Cytotoxic T-Lymphocyte Antigen-4):
   - Expressed on T-cells
   - **Inhibits T-cell activation** (early phase)
   - Competes with CD28 for B7 binding
   - Prevents T-cell priming

2. **PD-1** (Programmed Death-1):
   - Expressed on activated T-cells
   - **Inhibits T-cell effector function** (late phase)
   - Ligands: PD-L1, PD-L2
   - Prevents T-cell killing

**Cancer Immune Evasion**:
- Tumors express **PD-L1** → binds PD-1 on T-cells → **T-cell exhaustion**
- Tumor escapes immune destruction

**Immune Checkpoint Inhibitors**:
- **Block** inhibitory checkpoints
- **Unleash** T-cell anti-tumor activity
- "Remove the brakes" on immune system

---

## Checkpoint Inhibitors

### Anti-PD-1 Antibodies

#### Pembrolizumab (Keytruda)

**Mechanism**: **Monoclonal antibody against PD-1**
- Blocks PD-1/PD-L1 interaction
- **Reactivates T-cells** → tumor killing

**Clinical Uses** (Broad, expanding):
1. **Melanoma** (advanced) - first checkpoint inhibitor approved
2. **Non-small cell lung cancer (NSCLC)** - first-line (PD-L1 ≥50%)
3. **Head and neck squamous cell carcinoma**
4. **Urothelial carcinoma** (bladder)
5. **Renal cell carcinoma**
6. **Hodgkin lymphoma** (relapsed/refractory)
7. **Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors** - **any solid tumor** (tissue-agnostic approval)
8. **Triple-negative breast cancer**
9. Many others (expanding indications)

**Biomarkers**:
- **PD-L1 expression**: Predicts response (but not perfect)
  - ≥50%: Best response
  - Lower or negative: May still respond
- **MSI-H/dMMR**: High response rate (70-80%)
- **Tumor mutational burden (TMB)**: Higher TMB → better response

**Efficacy** (melanoma):
- **Response rate**: 40%
- **Durable responses**: Many patients remain in remission years later

**Dosing**: 200 mg IV q3 weeks or 400 mg IV q6 weeks

**Clinical Pearl**: **First-line NSCLC** if PD-L1 ≥50% (better than chemo)

#### Nivolumab (Opdivo)

**Mechanism**: **Anti-PD-1 mAb** (similar to pembrolizumab)

**Clinical Uses**: Similar to pembrolizumab
- Melanoma, NSCLC, RCC, bladder, head/neck, Hodgkin, hepatocellular carcinoma

**Combination**:
- **Nivolumab + Ipilimumab** (anti-CTLA-4): ↑efficacy, ↑toxicity
  - Melanoma, RCC

**Dosing**: 240 mg IV q2 weeks or 480 mg IV q4 weeks

#### Cemiplimab

**Mechanism**: Anti-PD-1

**Clinical Uses**: Cutaneous squamous cell carcinoma (advanced)

---

### Anti-PD-L1 Antibodies

#### Atezolizumab, Durvalumab, Avelumab

**Mechanism**: **Monoclonal antibodies against PD-L1**
- Block PD-L1/PD-1 interaction (same end result as anti-PD-1)

**Clinical Uses**:
- **Atezolizumab**: NSCLC, urothelial, breast (triple-negative)
- **Durvalumab**: NSCLC (stage III, post-chemoradiation consolidation)
- **Avelumab**: Merkel cell carcinoma, urothelial, RCC

**Note**: Similar efficacy and toxicity to anti-PD-1 antibodies

---

### Anti-CTLA-4 Antibodies

#### Ipilimumab (Yervoy)

**Mechanism**: **Monoclonal antibody against CTLA-4**
- Blocks CTLA-4 → **enhances T-cell priming**
- Works earlier in immune response than PD-1 inhibitors

**Clinical Uses**:
1. **Melanoma** (advanced):
   - Monotherapy or **combined with nivolumab** (combination superior)
2. **Renal cell carcinoma** (with nivolumab)
3. **Colorectal cancer** (MSI-H, with nivolumab)

**Efficacy** (melanoma monotherapy):
- **Long-term survival**: 20% alive at 10 years (unprecedented before immunotherapy)

**Combination Therapy** (Ipilimumab + Nivolumab):
- **Higher response rates** than either alone (melanoma 60% vs. 40-45%)
- **More toxicity** (see below)

**Dosing**:
- Monotherapy: 3 mg/kg IV q3 weeks × 4 doses
- Combination: 1 mg/kg ipilimumab + 3 mg/kg nivolumab q3 weeks × 4, then nivolumab alone

**Clinical Pearl**: **Combination with nivolumab** superior but more toxic

---

## Immune-Related Adverse Events (irAEs)

**Mechanism**: Immune system activation → autoimmunity

**Unique to Immunotherapy**:
- Different from traditional chemo toxicity
- **Can affect any organ**
- **Delayed onset** (weeks to months)
- **May require immunosuppression** (steroids)

**Grading**: Grade 1 (mild) to Grade 4 (life-threatening)

**Management Principles**:
1. **Early recognition** crucial
2. **High-dose steroids** (grade 2-4):
   - Prednisone 1-2 mg/kg/day
3. **Hold checkpoint inhibitor** (grade 2-3)
4. **Discontinue permanently** (grade 4 or severe)
5. **Additional immunosuppression** if steroid-refractory (infliximab, mycophenolate)

### Common irAEs

#### Dermatologic (Most Common, 30-40%)

**Manifestations**:
- **Rash**, pruritus (itching)
- Vitiligo (depigmentation)

**Timing**: Early (weeks)

**Management**:
- **Grade 1-2**: Topical steroids, antihistamines
- **Grade 3-4**: Systemic steroids, hold drug

#### Gastrointestinal/Hepatic (10-20%)

**Colitis**:
- **Diarrhea**, abdominal pain, blood in stool
- More common with **anti-CTLA-4** (ipilimumab 30-40%)

**Management**:
- **Grade 2-3**: Hold drug, high-dose steroids
- **Grade 4**: Discontinue permanently, steroids, consider infliximab
- **Rule out infection** (C. difficile, CMV)

**Hepatitis**:
- ↑AST, ALT (often asymptomatic)
- Monitor LFTs regularly

**Management**:
- **Grade 2-3**: Hold drug, steroids
- **Grade 4**: Discontinue permanently

#### Endocrine (5-10%)

**Thyroiditis** (Most Common Endocrine):
- **Hyperthyroidism** → **hypothyroidism** (destructive thyroiditis)
- Fatigue, weight changes

**Management**:
- **Hyperthyroidism**: β-blockers (symptom control)
- **Hypothyroidism**: Levothyroxine (lifelong)
- **Usually don't need to stop checkpoint inhibitor**

**Hypophysitis** (Pituitary Inflammation):
- **Hypopituitarism** (ACTH, TSH, LH/FSH deficiency)
- Headache, fatigue, hypotension
- More common with **anti-CTLA-4**

**Management**:
- **Hormone replacement** (hydrocortisone, levothyroxine, etc.)
- **Lifelong** replacement usually required

**Type 1 Diabetes Mellitus**:
- New-onset DKA
- Rare but serious

**Adrenal Insufficiency** (Primary):
- Rare

**Management Endocrine irAEs**:
- **Hormone replacement** (usually lifelong)
- **Usually can continue checkpoint inhibitor** (unlike other irAEs)

#### Pneumonitis (1-5%)

**Manifestations**:
- Dyspnea, cough, hypoxia
- Infiltrates on imaging

**Timing**: Median 2-3 months (variable)

**Severity**: Can be life-threatening

**Management**:
- **Grade 1**: Monitor
- **Grade 2**: Hold drug, consider steroids
- **Grade 3-4**: Discontinue permanently, high-dose steroids
- **Rule out infection**, pulmonary embolism

**Clinical Pearl**: **High index of suspicion** - can be fatal

#### Neurologic (Rare, <2%)

**Manifestations**:
- Guillain-Barré syndrome
- Myasthenia gravis
- Encephalitis
- Peripheral neuropathy

**Severity**: Can be life-threatening

**Management**:
- Discontinue drug
- High-dose steroids, IVIG, plasmapheresis (severe cases)

#### Cardiac (Rare, <1%)

**Myocarditis**:
- **Life-threatening** (can be fatal)
- Troponin elevation, arrhythmias, heart failure

**Management**:
- Discontinue permanently
- High-dose steroids, other immunosuppression

#### Renal (Rare)

**Nephritis**:
- ↑Creatinine, proteinuria

**Management**: Steroids, hold drug

#### Rheumatologic

**Arthritis, myositis**:
- Joint pain, muscle weakness

**Management**: NSAIDs, steroids (if severe)

### Frequency and Severity

**Incidence (Any Grade)**:
- **Anti-PD-1/PD-L1**: 60-80%
- **Anti-CTLA-4**: 70-90%
- **Combination** (ipilimumab + nivolumab): 95%

**Severe (Grade 3-4)**:
- **Anti-PD-1/PD-L1**: 10-20%
- **Anti-CTLA-4**: 20-30%
- **Combination**: 55-60%

**Fatal irAEs**: <1% overall (myocarditis, pneumonitis, colitis most common causes)

**Onset**: Variable (days to months, even after stopping)

**Duration**: Usually resolve with treatment, but some permanent (endocrine)

### Management Algorithm

**Grade 1** (Mild):
- **Continue checkpoint inhibitor**
- Symptomatic management
- Monitor closely

**Grade 2** (Moderate):
- **Hold checkpoint inhibitor**
- **Prednisone 0.5-1 mg/kg/day**
- Resume if resolves to grade 1 within 4-6 weeks

**Grade 3** (Severe):
- **Hold checkpoint inhibitor**
- **Prednisone 1-2 mg/kg/day** (or methylprednisolone IV)
- **Consider permanent discontinuation** (case-by-case)

**Grade 4** (Life-Threatening):
- **Discontinue checkpoint inhibitor permanently**
- **High-dose steroids**
- **Additional immunosuppression** if steroid-refractory (infliximab, mycophenolate)
- **ICU care**

**Exceptions**:
- **Endocrine irAEs**: Usually can continue checkpoint inhibitor (hormone replacement)

---

## CAR-T Cell Therapy

**Mechanism**: Chimeric Antigen Receptor T-Cell Therapy
- Patient's T-cells collected (leukapheresis)
- **Genetically engineered** to express CAR (recognizes tumor antigen)
- Expanded ex vivo
- Infused back into patient
- **CAR-T cells kill tumor cells** expressing target antigen

**Approved CAR-T Products**:

### Tisagenlecleucel (Kymriah)

**Target**: CD19 (B-cell marker)

**Clinical Uses**:
1. **Acute lymphoblastic leukemia (ALL)** - pediatric/young adult, relapsed/refractory
2. **Diffuse large B-cell lymphoma (DLBCL)** - relapsed/refractory

### Axicabtagene Ciloleucel (Yescarta)

**Target**: CD19

**Clinical Uses**: **Diffuse large B-cell lymphoma (DLBCL)** - relapsed/refractory

### Brexucabtagene Autoleucel (Tecartus)

**Target**: CD19

**Clinical Uses**: **Mantle cell lymphoma** - relapsed/refractory

### Idecabtagene Vicleucel, Ciltacabtagene Autoleucel

**Target**: BCMA (B-cell maturation antigen)

**Clinical Uses**: **Multiple myeloma** - relapsed/refractory

### Efficacy

**ALL** (tisagenlecleucel):
- **Complete remission**: 80%
- **Durable responses**: Many patients

**DLBCL**:
- **Complete remission**: 40-50%

### Toxicities

#### Cytokine Release Syndrome (CRS)

**Mechanism**: Massive cytokine release (IL-6, IFN-γ) from activated CAR-T cells and immune cells

**Clinical Features**:
- **Fever** (hallmark)
- **Hypotension**, tachycardia
- Hypoxia
- **Multi-organ dysfunction** (severe cases)

**Timing**: 1-14 days post-infusion (median 3 days)

**Severity**: Grade 1 (fever only) to Grade 4 (life-threatening)

**Management**:
- **Supportive care**: Fluids, vasopressors, oxygen
- **Tocilizumab** (anti-IL-6 receptor antibody):
  - **First-line for grade 2-4 CRS**
  - Reverses CRS rapidly
  - Dose: 8 mg/kg IV (can repeat)
- **Corticosteroids** (if tocilizumab insufficient)

**Clinical Pearl**: **Tocilizumab essential** (have available)

#### Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

**Manifestations**:
- **Encephalopathy**, confusion, delirium
- Aphasia, seizures
- **Cerebral edema** (severe)

**Timing**: 4-10 days post-infusion (often after CRS)

**Severity**: Grade 1-5

**Management**:
- **Corticosteroids** (dexamethasone)
- **Supportive care**
- **Seizure prophylaxis** (levetiracetam) - consider
- **ICU monitoring** (severe cases)

**Note**: **Tocilizumab does NOT treat ICANS** (may worsen - CNS IL-6 protective)

#### B-Cell Aplasia

**Mechanism**: CAR-T cells target CD19 (normal B-cells)

**Result**: **Hypogammaglobulinemia** (↑infection risk)

**Management**:
- **IVIG replacement**
- Monitor immunoglobulins

**Duration**: Months to years (as long as CAR-T cells persist)

### Other Considerations

**Manufacturing Time**: 2-4 weeks (patient must bridge with chemo)

**Cost**: >$400,000 per treatment

**Availability**: Specialized centers only

**Durability**: Long-term remissions possible (years)

---

## Other Immunotherapies

### Cytokines

#### Interleukin-2 (IL-2, Aldesleukin)

**Mechanism**: T-cell growth factor

**Clinical Uses**:
- **Melanoma** (high-dose)
- **Renal cell carcinoma**

**Toxicity**:
- **Capillary leak syndrome**: Hypotension, pulmonary edema, multi-organ failure
- **Requires ICU** (high-dose)

**Status**: Largely replaced by checkpoint inhibitors (better tolerability)

#### Interferon-α

**Clinical Uses**:
- Melanoma (adjuvant - historical)
- CML, hairy cell leukemia

**Toxicity**: Flu-like symptoms, depression, myelosuppression

**Status**: Largely replaced by better-tolerated agents

### Cancer Vaccines

**Sipuleucel-T** (Provenge):
- Autologous cellular immunotherapy
- **Prostate cancer** (metastatic, castration-resistant)
- Modest survival benefit

**HPV Vaccine** (Gardasil):
- **Prevents** cervical, oropharyngeal, other HPV-related cancers
- Prophylactic (not therapeutic)

### Oncolytic Viruses

**Talimogene Laherparepvec (T-VEC)**:
- Modified herpes simplex virus
- **Intralesional injection** (melanoma lesions)
- Local and systemic anti-tumor effect

---

## Clinical Pearls

1. **Checkpoint inhibitors** block immune checkpoints (PD-1, CTLA-4) → unleash T-cell anti-tumor activity
2. **Pembrolizumab/nivolumab**: Anti-PD-1, broad uses (melanoma, NSCLC, many others), durable responses
3. **Ipilimumab**: Anti-CTLA-4, melanoma, combination with nivolumab ↑efficacy/toxicity
4. **irAEs**: Autoimmune toxicities (any organ), manage with steroids, hold/discontinue drug
5. **Pneumonitis, colitis, hepatitis**: High index of suspicion, can be life-threatening
6. **Endocrine irAEs**: Hormone replacement, usually continue checkpoint inhibitor
7. **CAR-T**: CD19-targeted (B-cell malignancies), high response rates, CRS and ICANS main toxicities
8. **CRS**: Fever, hypotension, treat with tocilizumab (anti-IL-6)
9. **ICANS**: Encephalopathy, treat with steroids (NOT tocilizumab)
10. **Biomarkers**: PD-L1, MSI-H/dMMR, TMB predict response to checkpoint inhibitors

---

## Key Takeaways

1. **Checkpoint inhibitors**: Block PD-1/PD-L1 or CTLA-4 → activate T-cells
2. **PD-1 inhibitors** (pembrolizumab, nivolumab): Many cancers, PD-L1 expression predicts response
3. **CTLA-4 inhibitor** (ipilimumab): Melanoma, combination with PD-1 inhibitor ↑efficacy
4. **irAEs**: Autoimmune toxicities (dermatologic, GI, hepatic, endocrine, pneumonitis)
5. **irAE management**: Steroids (grade 2-4), hold drug (grade 2-3), discontinue (grade 4)
6. **Endocrine irAEs**: Hormone replacement, usually continue drug
7. **Pneumonitis, myocarditis**: Life-threatening, discontinue drug
8. **CAR-T**: Genetically engineered T-cells target tumor antigen (CD19, BCMA)
9. **CAR-T toxicity**: CRS (tocilizumab), ICANS (steroids), B-cell aplasia (IVIG)
10. **Durable responses**: Checkpoint inhibitors and CAR-T can achieve long-term remissions

---

## References

1. Katzung's Basic & Clinical Pharmacology, 15th Edition
2. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 11th Edition
3. NCCN Clinical Practice Guidelines in Oncology
4. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010.
5. Brahmer J, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015.
6. Neelapu SS, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017.
7. FDA Guidance - Immune-Related Adverse Events with Checkpoint Inhibitors
